New prophylaxis regimen for SARS-CoV-2 infection in health professionals with low doses of hydroxychloroquine and bromhexine: a randomised, double-blind placebo clinical trial (ELEVATE Trial)

INTRODUCTION: SARS-CoV-2 infection in Mexico has caused ~2.7 million confirmed cases; around 20%–25% of health workers will be infected by the virus at their workplace, with approximately 4.4% of mortality. High infectivity of SARS-CoV-2 is related with cell entry mechanism, through the ACE receptor...

Descripción completa

Detalles Bibliográficos
Autores principales: Granados-Montiel, Julio, Hazan-Lasri, Eric, Franco-Cendejas, Rafael, Chávez-Heres, Tatiana, Silva-Bermudez, Phaedra, Aguilar-Gaytán, Rocio, Manzano-León, Natalia, Méndez-Maldonado, Karla, Alvarez-Arce, Alejandro, Martínez-Portilla, Raigam Jafet
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Health Services Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338318/
https://www.ncbi.nlm.nih.gov/pubmed/34344672
http://dx.doi.org/10.1136/bmjopen-2020-045190

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8338318/
https://www.ncbi.nlm.nih.gov/pubmed/34344672
http://dx.doi.org/10.1136/bmjopen-2020-045190

Ejemplares similares